Loading...
XSHE
002581
Market cap690mUSD
Dec 05, Last price  
7.40CNY
1D
0.27%
1Q
-1.60%
Jan 2017
-69.51%
IPO
-9.24%
Name

Shandong Sinobioway Biomedicine Co Ltd

Chart & Performance

D1W1MN
XSHE:002581 chart
P/E
P/S
13.55
EPS
Div Yield, %
Shrs. gr., 5y
-19.06%
Rev. gr., 5y
-8.68%
Revenues
360m
-16.14%
150,029,741177,251,964213,798,562247,173,208246,369,291285,343,999317,253,572319,139,852858,285,7221,264,879,4361,162,416,642664,593,783567,637,225276,830,417402,713,045357,080,537429,790,105360,405,014
Net income
-137m
L-58.70%
32,632,81637,042,78058,823,81570,255,75566,976,25086,270,93888,037,32681,478,735250,253,848417,695,144388,411,585063,383,5060271,001,6710-332,458,291-137,313,572
CFO
-7m
L-82.07%
25,067,69546,888,20754,056,99585,712,12374,426,51563,035,34383,132,88380,108,148137,728,784169,315,097271,106,65574,456,07548,414,58118,510,19900-36,506,208-6,547,055
Dividend
Jun 21, 20160.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Sinobioway Biomedicine Co., Ltd. manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, nerve growth factor, and alfaron in China. The company also provides NOBEX, a murine nerve growth factor for injection; Anferon, a human recombinant interferon alpha 2b injection; and Jaferon, a human recombinant interferon alpha 2b spray. In addition, it offers Healive, an inactivated hepatitis A vaccine; Bilive, a combined hepatitis A and B Vaccine; Panflu, a pandemic influenza vaccine; Anflu, a preservative-free influenza virus vaccine; Panflu.1, a Type A H1N1 influenza vaccine; etc. Further, the company exports its products to approximately 20 counties and regions in Europe and the United States. Shandong Sinobioway Biomedicine Co., Ltd. was founded in 2000 and is headquartered in Zibo, China.
IPO date
May 20, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT